S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,251.80 (+0.06%)
DOW   39,789.67 (+0.07%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
NASDAQ:LIVN

LivaNova (LIVN) Stock Price, News & Analysis

$55.86
-0.01 (-0.02%)
(As of 09:30 AM ET)
Today's Range
$55.86
$55.86
50-Day Range
$48.60
$57.12
52-Week Range
$41.87
$59.86
Volume
5,271 shs
Average Volume
616,722 shs
Market Capitalization
$3.01 billion
P/E Ratio
174.57
Dividend Yield
N/A
Price Target
$64.40

LivaNova MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
15.3% Upside
$64.40 Price Target
Short Interest
Bearish
6.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of LivaNova in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.30%
From $3.01 to $3.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.36 out of 5 stars

Medical Sector

744th out of 939 stocks

Electromedical Equipment Industry

14th out of 20 stocks

LIVN stock logo

About LivaNova Stock (NASDAQ:LIVN)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

LIVN Stock Price History

LIVN Stock News Headlines

LivaNova (NASDAQ:LIVN) Receives Buy Rating from Mizuho
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
LivaNova PLC
LivaNova to Announce First-Quarter 2024 Results
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
LIVN Jan 2025 52.500 put
Mizuho Upgrades LivaNova (LIVN)
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
Here's what to expect from Livanova's earnings report
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:LIVN
Employees
2,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$64.40
High Stock Price Target
$75.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+15.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$17.55 million
Pretax Margin
-7.04%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Cash Flow
$4.42 per share
Book Value
$23.72 per share

Miscellaneous

Free Float
53,853,000
Market Cap
$3.01 billion
Optionable
Optionable
Beta
0.89
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Badri Amurthur
    Chief Technology Officer
  • Lindsey Little
    Senior Director of Investor Relations
  • Mr. Michael D. Hutchinson (Age 53)
    Senior VP, Chief Legal Officer & Company Secretary
  • Deanna Wilke
    Vice President of Corporate Communications
  • Mr. Matthew Joseph Dodds III
    Senior Vice President of Corporate Development & IT
  • Dr. Bryan D. Olin Ph.D. (Age 57)
    Senior VP & Head of Product Development - Neuromodulation
  • Mr. Ryan Miller
    President of Advanced Circulatory Support
  • Ms. Stephanie Bolton
    President of Global Epilepsy
  • Mr. John Webb
    Vice President of Sleep Apnea and Epilepsy
  • Mr. Jonathan Walker
    VP for Difficult-to-Treat Depression Segment

LIVN Stock Analysis - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings
or view top-rated stocks.

What is LivaNova's stock price target for 2024?

5 brokers have issued 12-month price objectives for LivaNova's shares. Their LIVN share price targets range from $52.00 to $75.00. On average, they expect the company's stock price to reach $64.40 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price.
View analysts price targets for LIVN
or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2024?

LivaNova's stock was trading at $51.74 at the beginning of the year. Since then, LIVN stock has increased by 8.0% and is now trading at $55.87.
View the best growth stocks for 2024 here
.

Are investors shorting LivaNova?

LivaNova saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,490,000 shares, an increase of 28.3% from the February 29th total of 2,720,000 shares. Based on an average daily volume of 627,400 shares, the days-to-cover ratio is currently 5.6 days.
View LivaNova's Short Interest
.

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LIVN earnings forecast
.

How can I listen to LivaNova's earnings call?

LivaNova will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings results on Wednesday, February, 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. The business earned $310.10 million during the quarter, compared to analyst estimates of $287.65 million. LivaNova had a trailing twelve-month return on equity of 12.23% and a net margin of 1.53%. LivaNova's revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.81 EPS.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of $2.95-3.05 for the period, compared to the consensus earnings per share estimate of $2.99.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?
Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (10.75%), Vanguard Group Inc. (3.29%), Vanguard Group Inc. (3.28%), Dimensional Fund Advisors LP (2.31%), Greenlight Capital Inc. (2.28%) and Barclays PLC (1.80%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends
.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIVN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners